Since the first PDUFA date for Alexza, the company has always indicated that it would be approximately 6 months from the approval date to when product is made available for sale. They have been clear that the long lead-time is for there device supply chain scale-up, which could not be started until the produt was approved. Those that are "surprised" are clearly not very informed.
Look at the PR's. It is there. They are doing it because they are cash-strapped and needed to dilute to raise more money to manufacture their drug. Look at NPSP, their drug got approved in December and it will be in the market already by February. Avoid investing in a fly-by-night company like ALXA. Their stock is good for short term trading only.
Can't believe anyone would post strong sell=Hell its only a 50 cent stock when you consider reverse spit. Won't go alot lower, IMHO- I believe the company will be bought-Big question is for what price.
"The approval of ADASUVE is an important event in the treatment of agitation. ADASUVE is the first approved non-injectable therapy for the acute treatment of agitation in adults with schizophrenia and bipolar I disorder. As noted in the consensus guidelines for Best Practices in the Evaluation and Treatment of Agitation, we believe that the ability to deliver medications rapidly and non-invasively will be important for patients and the professionals who care for them," said Thomas B. King, President and CEO of Alexza. "This is a landmark day for Alexza and we are proud of our accomplishments in developing this unique product. We project that ADASUVE will be available for commercial launch early in the third quarter of 2013."